FDA granted Fast Track designation to AG-120 for the treatment of patients with acute myelogenous leukemia who harbor an isocitrate dehydrogenase-1 (IDH1) mutation.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe